Predictive value of remnant cholesterol for left ventricular hypertrophy and prognosis in hypertensive patients with heart failure: a prospective study
Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patient...
Saved in:
Published in | Lipids in health and disease Vol. 23; no. 1; pp. 294 - 9 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
12.09.2024
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1476-511X 1476-511X |
DOI | 10.1186/s12944-024-02282-y |
Cover
Loading…
Abstract | Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses.
Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001).
RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality.
NCT03727828, 21 Oct 2018. |
---|---|
AbstractList | Abstract Background and Aim Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients’ prognoses. Methods and results Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62–2.26 vs. HR: 1.75, 95% CI: 1.43–2.16, P < 0.001). Conclusions RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality. Trial registration NCT 03727828, 21 Oct 2018. Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses. Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001). RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality. Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses. Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001). RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality. NCT03727828, 21 Oct 2018. Background and Aim Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses. Methods and results Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001). Conclusions RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality. Trial registration NCT 03727828, 21 Oct 2018. Keywords: Remnant cholesterol (RC), Hypertension, Heart failure (HF), Left ventricular hypertrophy (LVH), Prognosis Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses.BACKGROUND AND AIMRemnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often develop left ventricular hypertrophy (LVH) and have poor prognoses. This study investigated baseline RC levels and LV remodelling and patients' prognoses.Six hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001).METHODS AND RESULTSSix hundred thirty consecutive individuals with hypertension and HF participated in this prospective trial from October 2018 to August 2020. Based on left ventricular mass index (LVMI), 560 those eligible were separated into LVH and non-LVH groups. Multiple linear regression and receiver operating characteristic (ROC) curves examined the RC and LV relationship. A Cox regression analysis was conducted to examine the predictive value of RC for clinical outcomes. The LVH group presented significantly elevated values of RC, triglyceride, and cholesterol and decreased high-density lipoprotein cholesterol (HDLC). The optimal cutoff value for RC to predict LV remodelling was 0.49. The subjects were observed for a median of 58 months, and 104 participants met the primary endpoint. The risk models involving the two Cox models were adjusted to incorporate confounding factors, which revealed that those with elevated baseline levels of RC were more susceptible to cardiovascular mortality, as shown by an increased hazard ratio. (HR: 1.91, 95% CI: 1.62-2.26 vs. HR: 1.75, 95% CI: 1.43-2.16, P < 0.001).RC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality.CONCLUSIONSRC is linked to LV remodelling in patients with hypertensive HF, with LVH having greater RC values. Moreover, patients with hypertensive HF who had a higher RC suffered from an increased risk of cardiovascular mortality.NCT03727828, 21 Oct 2018.TRIAL REGISTRATIONNCT03727828, 21 Oct 2018. |
ArticleNumber | 294 |
Audience | Academic |
Author | Xu, Yawei Wang, Ting Liu, Weijing Wang, Zeyu Jiang, Dongyang Shen, Jianying Zhang, Yan Zhu, Zhaoxin |
Author_xml | – sequence: 1 givenname: Zeyu surname: Wang fullname: Wang, Zeyu – sequence: 2 givenname: Zhaoxin surname: Zhu fullname: Zhu, Zhaoxin – sequence: 3 givenname: Jianying surname: Shen fullname: Shen, Jianying – sequence: 4 givenname: Yan surname: Zhang fullname: Zhang, Yan – sequence: 5 givenname: Ting surname: Wang fullname: Wang, Ting – sequence: 6 givenname: Yawei surname: Xu fullname: Xu, Yawei – sequence: 7 givenname: Dongyang surname: Jiang fullname: Jiang, Dongyang – sequence: 8 givenname: Weijing surname: Liu fullname: Liu, Weijing |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39267042$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kt2K1TAUhYuMOD_6Al5IwBtvOiZpmjbeyDD4MzCgFwrehTTZOc3Qk9SkPcN5El_XdHocZkQkhJSdtT52d9ZpceSDh6J4SfA5IS1_mwgVjJWYLpu2tNw_KU4Ia3hZE_Lj6MH3cXGa0g3GFDecPyuOK0F5gxk9KX59jWCcntwO0E4NM6BgUYStV35Cug8DpAliGJANEQ1gJ7QDP0Wn50FF1O9HiFMMY79Hyhs0xrDxIbmEnD9cgk8Le1STy8aEbt3Uox5UnJBVbpgjvENqMaYR1jbSNJv98-KpVUOCF4fzrPj-8cO3y8_l9ZdPV5cX16WuKz6VlhqrFNOEE0YbXWOr69aKphNCdFWtOGeGdUTUjIjKdFR1QFsuFKE17rQW1VlxtXJNUDdyjG6r4l4G5eRdIcSNzK06PYAE20BbUQVMGcag6lqmjYGGmVy0Nc-s9ytrnLstGL0MSg2PoI9vvOvlJuwkIZUgLaOZ8OZAiOHnnEcvty5pGAblIcxJVgQzXAmBSZa-XqUblXtz3oaM1ItcXrS4rTmuyAI8_4cqLwNbp3OcrMv1R4ZXD__hvvk_ickCugp0frIUwd5LCJZLLOUaS5ljKe9iKffZ1P5l0m7KiQjLHNzwP-tv46TsBQ |
CitedBy_id | crossref_primary_10_1016_j_atherosclerosis_2025_119129 |
Cites_doi | 10.1016/j.pcad.2019.11.009 10.1016/j.cca.2018.12.014 10.1016/j.jacc.2020.10.008 10.1016/j.ahj.2008.07.004 10.7326/AITC201712050 10.3399/BJGP.2023.0328 10.1186/s12933-022-01554-0 10.1016/j.cjca.2017.07.015 10.1016/j.pcad.2014.05.003 10.1016/j.jacc.2020.01.014 10.1093/eurheartj/eht133 10.1093/eurheartj/ehab293 10.1097/MOL.0000000000000330 10.1186/s12933-020-01076-7 10.1111/jch.12282 10.1111/joim.13059 10.1016/j.jacc.2020.09.583 10.1186/s12933-016-0454-x 10.1093/eurheartj/ehab368 10.1093/eurheartj/ehab705 10.1161/HYPERTENSIONAHA.108.114439 10.1093/eurheartj/ehy339 10.1093/ehjqcco/qcad030 10.3389/fcvm.2023.1063562 10.1161/CIRCIMAGING.123.015589 10.1161/CIRCIMAGING.115.004426 10.1530/EC-23-0476 10.3390/jcm10153388 10.1007/s00125-023-06016-0 10.3389/fcvm.2022.993097 10.1016/j.healun.2009.04.026 10.3389/fcvm.2022.938647 10.1016/j.numecd.2023.02.009 10.1186/s12933-017-0519-5 10.1186/s12933-018-0773-1 |
ContentType | Journal Article |
Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. The Author(s) 2024 2024 |
Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: The Author(s) 2024 2024 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s12944-024-02282-y |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1476-511X |
EndPage | 9 |
ExternalDocumentID | oai_doaj_org_article_ef7e832ae4ad44e3b84cdde74d32af56 PMC11391842 A808560312 39267042 10_1186_s12944_024_02282_y |
Genre | Journal Article |
GeographicLocations | China Canada Taiwan |
GeographicLocations_xml | – name: China – name: Canada – name: Taiwan |
GrantInformation_xml | – fundername: Science and Technology Commission of Shanghai Municipality grantid: No. 22Y11910000 |
GroupedDBID | --- 0R~ 29L 2WC 53G 5GY 5VS 7X7 88E 8FE 8FH 8FI 8FJ A8Z AAFWJ AAHBH AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACPRK ACUHS ADBBV ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IGS IHR INH INR ITC KQ8 LK8 M1P M48 M7P M~E O5R O5S OK1 OVT P2P P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB PMFND 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c536t-f2dfaa4c161427c50fc58f97b999b35a664d4b1954193db2abe2869a1250bcc93 |
IEDL.DBID | M48 |
ISSN | 1476-511X |
IngestDate | Wed Aug 27 01:20:31 EDT 2025 Thu Aug 21 18:34:22 EDT 2025 Thu Jul 10 22:25:58 EDT 2025 Tue Jun 17 22:03:35 EDT 2025 Tue Jun 10 21:04:29 EDT 2025 Mon Jul 21 06:03:34 EDT 2025 Thu Apr 24 23:09:17 EDT 2025 Tue Jul 01 00:23:23 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Hypertension Prognosis Left ventricular hypertrophy (LVH) Remnant cholesterol (RC) Heart failure (HF) |
Language | English |
License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c536t-f2dfaa4c161427c50fc58f97b999b35a664d4b1954193db2abe2869a1250bcc93 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/ef7e832ae4ad44e3b84cdde74d32af56 |
PMID | 39267042 |
PQID | 3104039901 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ef7e832ae4ad44e3b84cdde74d32af56 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11391842 proquest_miscellaneous_3104039901 gale_infotracmisc_A808560312 gale_infotracacademiconefile_A808560312 pubmed_primary_39267042 crossref_primary_10_1186_s12944_024_02282_y crossref_citationtrail_10_1186_s12944_024_02282_y |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-09-12 |
PublicationDateYYYYMMDD | 2024-09-12 |
PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-12 day: 12 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | Lipids in health and disease |
PublicationTitleAlternate | Lipids Health Dis |
PublicationYear | 2024 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | J Park (2282_CR33) 2017; 16 B Williams (2282_CR11) 2018; 39 PG Jørgensen (2282_CR9) 2016; 15 S Gao (2282_CR14) 2017; 33 A Varbo (2282_CR19) 2021; 42 J Borén (2282_CR18) 2016; 27 MR Mehra (2282_CR6) 2009; 28 ER Rietzschel (2282_CR13) 2008; 52 L Zhao (2282_CR31) 2023; 10 2282_CR17 J Liu (2282_CR20) 2022; 9 TB Horwich (2282_CR5) 2008; 156 L Kopin (2282_CR3) 2017; 167 JM de Hartog-Keyzer (2282_CR30) 2024; 74 J Deng (2282_CR24) 2023; 33 G Su (2282_CR16) 2014; 16 CJ Lavie (2282_CR2) 2014; 57 N Aung (2282_CR4) 2020; 76 X Hu (2282_CR28) 2022; 21 A Langsted (2282_CR23) 2020; 288 BN Wadström (2282_CR27) 2022; 43 S Ida (2282_CR32) 2018; 17 R Wang (2282_CR15) 2023; 9 TA McDonagh (2282_CR12) 2021; 42 2282_CR21 O Castañer (2282_CR26) 2020; 76 H Liu (2282_CR8) 2022; 9 EY Choi (2282_CR29) 2013; 34 2282_CR25 H Tada (2282_CR7) 2019; 490 X Xu (2282_CR10) 2023; 16 SP Murphy (2282_CR22) 2020; 75 M Yildiz (2282_CR1) 2020; 63 YX Cao (2282_CR34) 2020; 19 BN Wadström (2282_CR35) 2023; 66 |
References_xml | – volume: 63 start-page: 10 issue: 1 year: 2020 ident: 2282_CR1 publication-title: Prog Cardiovasc Dis doi: 10.1016/j.pcad.2019.11.009 – volume: 490 start-page: 1 year: 2019 ident: 2282_CR7 publication-title: Clin Chim Acta doi: 10.1016/j.cca.2018.12.014 – volume: 76 start-page: 2712 issue: 23 year: 2020 ident: 2282_CR26 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.10.008 – volume: 156 start-page: 1170 issue: 6 year: 2008 ident: 2282_CR5 publication-title: Am Heart J doi: 10.1016/j.ahj.2008.07.004 – volume: 167 start-page: Itc81 issue: 11 year: 2017 ident: 2282_CR3 publication-title: Ann Intern Med doi: 10.7326/AITC201712050 – volume: 74 start-page: e219 issue: 741 year: 2024 ident: 2282_CR30 publication-title: Br J Gen Pract doi: 10.3399/BJGP.2023.0328 – volume: 21 start-page: 117 issue: 1 year: 2022 ident: 2282_CR28 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-022-01554-0 – volume: 33 start-page: 1624 issue: 12 year: 2017 ident: 2282_CR14 publication-title: Can J Cardiol doi: 10.1016/j.cjca.2017.07.015 – volume: 57 start-page: 3 issue: 1 year: 2014 ident: 2282_CR2 publication-title: Prog Cardiovasc Dis doi: 10.1016/j.pcad.2014.05.003 – volume: 75 start-page: 1324 issue: 11 year: 2020 ident: 2282_CR22 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.01.014 – volume: 34 start-page: 2354 issue: 30 year: 2013 ident: 2282_CR29 publication-title: Eur Heart J doi: 10.1093/eurheartj/eht133 – volume: 42 start-page: 4833 issue: 47 year: 2021 ident: 2282_CR19 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehab293 – volume: 27 start-page: 473 issue: 5 year: 2016 ident: 2282_CR18 publication-title: Curr Opin Lipidol doi: 10.1097/MOL.0000000000000330 – volume: 19 start-page: 104 issue: 1 year: 2020 ident: 2282_CR34 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-020-01076-7 – volume: 16 start-page: 192 issue: 3 year: 2014 ident: 2282_CR16 publication-title: J Clin Hypertens (Greenwich) doi: 10.1111/jch.12282 – volume: 288 start-page: 116 issue: 1 year: 2020 ident: 2282_CR23 publication-title: J Intern Med doi: 10.1111/joim.13059 – volume: 76 start-page: 2477 issue: 21 year: 2020 ident: 2282_CR4 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2020.09.583 – volume: 15 start-page: 137 issue: 1 year: 2016 ident: 2282_CR9 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-016-0454-x – volume: 42 start-page: 3599 issue: 36 year: 2021 ident: 2282_CR12 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehab368 – volume: 43 start-page: 3258 issue: 34 year: 2022 ident: 2282_CR27 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehab705 – volume: 52 start-page: 535 issue: 3 year: 2008 ident: 2282_CR13 publication-title: Hypertension doi: 10.1161/HYPERTENSIONAHA.108.114439 – volume: 39 start-page: 3021 issue: 33 year: 2018 ident: 2282_CR11 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehy339 – volume: 9 start-page: 537 issue: 5 year: 2023 ident: 2282_CR15 publication-title: Eur Heart J Qual Care Clin Outcomes doi: 10.1093/ehjqcco/qcad030 – volume: 10 start-page: 1063562 year: 2023 ident: 2282_CR31 publication-title: Front Cardiovasc Med doi: 10.3389/fcvm.2023.1063562 – volume: 16 start-page: e015589 issue: 11 year: 2023 ident: 2282_CR10 publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.123.015589 – ident: 2282_CR21 doi: 10.1161/CIRCIMAGING.115.004426 – ident: 2282_CR17 doi: 10.1530/EC-23-0476 – ident: 2282_CR25 doi: 10.3390/jcm10153388 – volume: 66 start-page: 2238 issue: 12 year: 2023 ident: 2282_CR35 publication-title: Diabetologia doi: 10.1007/s00125-023-06016-0 – volume: 9 start-page: 993097 year: 2022 ident: 2282_CR20 publication-title: Front Cardiovasc Med doi: 10.3389/fcvm.2022.993097 – volume: 28 start-page: 876 issue: 9 year: 2009 ident: 2282_CR6 publication-title: J Heart Lung Transpl doi: 10.1016/j.healun.2009.04.026 – volume: 9 start-page: 938647 year: 2022 ident: 2282_CR8 publication-title: Front Cardiovasc Med doi: 10.3389/fcvm.2022.938647 – volume: 33 start-page: 1049 issue: 5 year: 2023 ident: 2282_CR24 publication-title: Nutr Metab Cardiovasc Dis doi: 10.1016/j.numecd.2023.02.009 – volume: 16 start-page: 36 issue: 1 year: 2017 ident: 2282_CR33 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-017-0519-5 – volume: 17 start-page: 129 issue: 1 year: 2018 ident: 2282_CR32 publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-018-0773-1 |
SSID | ssj0020766 |
Score | 2.3710046 |
Snippet | Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart failure (HF) often... Background and Aim Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension and heart... Abstract Background and Aim Remnant cholesterol (RC) is substantially related to negative outcomes in cardiac patients. Patients with coexisting hypertension... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 294 |
SubjectTerms | Aged Analysis Antihypertensive drugs Antilipemic agents Canada Cholesterol Cholesterol - blood Cholesterol, HDL - blood Complications and side effects Female Health aspects Heart Heart enlargement Heart failure Heart failure (HF) Heart Failure - blood Heart Failure - complications Heart Failure - mortality Humans Hypertension Hypertension - blood Hypertension - complications Hypertrophy, Left Ventricular - blood Left ventricular hypertrophy (LVH) Male Medical research Medicine, Experimental Middle Aged Mortality Physiological aspects Prognosis Proportional Hazards Models Prospective Studies Remnant cholesterol (RC) Risk Factors ROC Curve Taiwan Triglycerides Triglycerides - blood Ventricular Remodeling |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pi9UwEA6yB_EiuuuP6iojiB4kbF-Tpq23p7gswooHF_YWkjRhH7xtpe0e3l_iv-tM2j5eEfTi7b0khTQzmfkmnXzD2FsvS2fSPOdeCsulkBmvitrxoCplsKkIKd0dvvymLq7k1-v8-qDUF-WEjfTA48Kd-VB41Drjpaml9MKW0uGWLGSNjSGPZNvo8-Zgagq1MDpX8xWZUp316NWk5OiPOPG9ZHy3cEORrf9Pm3zglJYJkwce6PwRezhBR1iPU37M7vnmmJ2sGwybb3fwDmIyZzwlP2b3L6dv5ifs1_eOfpNZA6L29tAG6PwtZcAAGb_IldBuAeErbH0YgFIg47mg6eAG49Ru6FqUBpimBsrnatp-08OmmTrHFHiYGFp7oKNdoELZAwSzobT3j2DowflWJ0RO2yfs6vzLj88XfCrHwF0u1MBDVgdjpEOMKLPC5WlweRmqwiLGtCI3SslaWmKQQ1BY28xYn5WqMgihUutcJZ6yo6Zt_HMGofIrxF1V6hGO2VWNf0WVOyERYPrUi4StZuloN3GVU8mMrY4xS6n0KFGNEtVRonqXsA_7Z36OTB1_Hf2JhL4fSSzbsQF1T0-6p_-lewl7TyqjyRbg9JyZrjTgSxKrll6XCGipjHeWsNPFSNzDbtH9ZlY6TV2U-Nb49q7XiL5lKujjZcKejUq4nzNCW1Wg0U1YuVDPxUste5rNTaQQX-F6Y2yfvfgfy_CSPcji1qLCGqfsaOju_CuEaoN9HXflb5OuQK4 priority: 102 providerName: Directory of Open Access Journals |
Title | Predictive value of remnant cholesterol for left ventricular hypertrophy and prognosis in hypertensive patients with heart failure: a prospective study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39267042 https://www.proquest.com/docview/3104039901 https://pubmed.ncbi.nlm.nih.gov/PMC11391842 https://doaj.org/article/ef7e832ae4ad44e3b84cdde74d32af56 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ti9QwEA73AuIX0TtfqucSQfSDRLttmrSCyJ7ccQh7HOLCfgtpmtwt7LXa9sD9Jf5dZ9J2ueIh-G3bpEubmck8k0yeIeS15anRYZIwy-Oc8ZhHLJOFYU5kQsMt6UI8Ozw_F2cL_nWZLHfIUO6oH8DmztAO60kt6vX7Xz83n8HgP3mDT8WHBnwW5wy8DUM2l4htdsk-eCaJhjrn212FCGL27rSRFAyAxnI4RHPnf4wclefz_3vWvuW2ximVt3zU6UPyoAeXdNZpwyOyY8sDcjgrIbC-3tA31Kd7-nX0A3Jv3u-qH5LfFzX-xomPIvm3pZWjtb3GHBmKI-TZFKo1BYBL19a1FJMk_cqhrukVRLJ1W1cgL6rLgmLGV1k1q4auyr6xS5KnPYdrQ3Hxl2Ip7ZY6vcLE-I9U44PDuU_qWW8fk8XpyfcvZ6wv2MBMEouWuahwWnMDKJJH0iShM0nqMpkDCs3jRAvBC54jxxzAxiKPdG6jVGQaQFaYG5PFT8heWZX2GaEus1NAZlloAbDl0wIu4ywxMQcIakMbB2Q6SEeZns0ci2qslY9qUqE6iSqQqPISVZuAvNs-86Pj8vhn72MU-rYn8nD7G1V9qXqzVtZJC3OitlwXnNs4T7kBhyF5ATddIgLyFlVGof7C6xndH3qAj0TeLTVLAfJioe8oIEejnmDlZtT8alA6hU2YGlfa6qZRgM95GOP2ZkCedkq4fWcAv0LCtByQdKSeo48at5SrK08yPoXxhug_ev5fg_aC3I-8DWGNjSOy19Y39iWgtjafkF25lBOyf3xyfvFt4tc-Jt48_wBLWUN8 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Predictive+value+of+remnant+cholesterol+for+left+ventricular+hypertrophy+and+prognosis+in+hypertensive+patients+with+heart+failure%3A+a+prospective+study&rft.jtitle=Lipids+in+health+and+disease&rft.au=Wang%2C+Zeyu&rft.au=Zhu%2C+Zhaoxin&rft.au=Shen%2C+Jianying&rft.au=Zhang%2C+Yan&rft.date=2024-09-12&rft.issn=1476-511X&rft.eissn=1476-511X&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12944-024-02282-y&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12944_024_02282_y |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-511X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-511X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-511X&client=summon |